Condition (MeSH)
Angina Pectoris, Variant
ClinicalTrials.gov lists 34 trials for Angina Pectoris, Variant or a narrower condition beneath it. Korea Otsuka Pharmaceutical Co., Ltd. has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
34 of the 34 trials are tagged with Angina Pectoris, Variant itself; the rest are tagged with a narrower condition beneath it.
When did Angina Pectoris, Variant trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2018 | 1 |
| 2017 | 5 |
| 2016 | 1 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 10 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Angina Pectoris, Variant trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 2/3 | 2 |
| Phase 3 | 2 |
| Phase 4 | 8 |
| Not applicable | 10 |
| Observational | 10 |
How many Angina Pectoris, Variant trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 7 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 10 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Angina Pectoris, Variant trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Korea Otsuka Pharmaceutical Co., Ltd. | 3 |
| Roxane Laboratories | 2 |
Which drugs are being tested for Angina Pectoris, Variant? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| ATORVASTATIN | 3 |
| Cilostazol | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Amlodipine | 3 |
| Statin | 2 |
| Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed | 1 |
| Pharmacological treatment will be individualized according to the invasive coronary phenotype identified. Treatment may include antianginal therapy, vasodilator therapy, endothelial function-targeted | 1 |
| Antiplatelet Drug | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Angina Pectoris, Variant? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction. | Circulation journal : official journal of the Japanese Circulation Society | 2023 | Yes |
| Beyond Structural Angiography: The Emergence of Functional Coronary Angiography. | Journal of the American College of Cardiology | 2022 | Yes |
| The association of chronic air pollutants with coronary artery spasm, vasospastic angina, and endothelial dysfunction. | Coronary artery disease | 2018 | Yes |
| Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. | European heart journal | 2018 | Yes |
| Ultra-long acting calcium channel blockers may decrease accuracy of the acetylcholine provocation test. | International journal of cardiology | 2017 | Yes |
Showing 5 of 15 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.